This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. ALDX, GLSI, EPRX, LRMR, NKTX, RAPT, ENTA, NKTR, ATOS, and LYELShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Aldeyra Therapeutics (ALDX), Greenwich LifeSciences (GLSI), Eupraxia Pharmaceuticals (EPRX), Larimar Therapeutics (LRMR), Nkarta (NKTX), RAPT Therapeutics (RAPT), Enanta Pharmaceuticals (ENTA), Nektar Therapeutics (NKTR), Atossa Therapeutics (ATOS), and Lyell Immunopharma (LYEL). These companies are all part of the "medical" sector. Alterity Therapeutics vs. Aldeyra Therapeutics Greenwich LifeSciences Eupraxia Pharmaceuticals Larimar Therapeutics Nkarta RAPT Therapeutics Enanta Pharmaceuticals Nektar Therapeutics Atossa Therapeutics Lyell Immunopharma Alterity Therapeutics (NASDAQ:PRAN) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Do analysts recommend PRAN or ALDX? Aldeyra Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 327.93%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor PRAN or ALDX? In the previous week, Aldeyra Therapeutics had 19 more articles in the media than Alterity Therapeutics. MarketBeat recorded 19 mentions for Aldeyra Therapeutics and 0 mentions for Alterity Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.54 beat Alterity Therapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Alterity Therapeutics Neutral Aldeyra Therapeutics Positive Which has preferable earnings & valuation, PRAN or ALDX? Alterity Therapeutics has higher revenue and earnings than Aldeyra Therapeutics. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity Therapeutics$150K252.17-$6.40M-$0.70-6.07Aldeyra TherapeuticsN/AN/A-$37.54M-$0.97-2.29 Is PRAN or ALDX more profitable? Alterity Therapeutics' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Aldeyra Therapeutics N/A -43.01%-33.62% Do institutionals & insiders hold more shares of PRAN or ALDX? 3.6% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, PRAN or ALDX? Alterity Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Does the MarketBeat Community prefer PRAN or ALDX? Aldeyra Therapeutics received 298 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 69.43% of users gave Aldeyra Therapeutics an outperform vote while only 57.67% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformAlterity TherapeuticsOutperform Votes18857.67% Underperform Votes13842.33% Aldeyra TherapeuticsOutperform Votes48669.43% Underperform Votes21430.57% SummaryAldeyra Therapeutics beats Alterity Therapeutics on 9 of the 16 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.83M$6.46B$5.34B$8.30BDividend YieldN/A2.63%5.27%4.11%P/E Ratio-6.078.4426.9619.59Price / Sales252.17258.50398.81136.02Price / CashN/A65.8538.3234.64Price / Book3.046.416.774.50Net Income-$6.40M$143.95M$3.24B$248.60M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$4.25+0.5%N/A+112.5%$37.83M$150,000.00-6.0714Gap DownALDXAldeyra Therapeutics2.2115 of 5 stars$2.37-2.3%$9.50+301.7%-43.2%$143.15MN/A-2.4615Trending NewsAnalyst UpgradeAnalyst RevisionGLSIGreenwich LifeSciences1.1833 of 5 stars$10.56+3.7%$39.00+269.3%-26.8%$140.04MN/A-13.193Earnings ReportEPRXEupraxia Pharmaceuticals2.1182 of 5 stars$3.81-2.4%$10.50+176.0%+35.8%$136.41MN/A-5.2829LRMRLarimar Therapeutics2.1086 of 5 stars$2.05+5.1%$19.63+859.7%-73.6%$131.26MN/A-1.7830Positive NewsNKTXNkarta1.9402 of 5 stars$1.81+6.2%$14.67+712.6%-72.8%$128.43MN/A-0.96140RAPTRAPT Therapeutics4.2445 of 5 stars$0.97+0.1%$4.00+312.8%-70.6%$128.31M$1.53M-0.3580News CoverageAnalyst UpgradeAnalyst RevisionENTAEnanta Pharmaceuticals3.8431 of 5 stars$5.95-0.2%$17.25+189.9%-51.7%$127.19M$64.46M-1.20160NKTRNektar Therapeutics4.1471 of 5 stars$0.68-2.2%$4.50+561.8%-60.1%$125.77M$87.25M-0.80220Gap DownATOSAtossa Therapeutics2.0228 of 5 stars$0.95-3.6%$7.13+651.6%-43.0%$122.07MN/A-4.308Gap DownLYELLyell Immunopharma2.9289 of 5 stars$0.41-0.3%$1.00+142.7%-84.9%$122.00M$65,000.00-0.52270Positive NewsGap Down Related Companies and Tools Related Companies Aldeyra Therapeutics Competitors Greenwich LifeSciences Competitors Eupraxia Pharmaceuticals Competitors Larimar Therapeutics Competitors Nkarta Competitors RAPT Therapeutics Competitors Enanta Pharmaceuticals Competitors Nektar Therapeutics Competitors Atossa Therapeutics Competitors Lyell Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
